153 related articles for article (PubMed ID: 18327991)
1. Treatment of hypertension in individuals with the cardiometabolic syndrome: role of an angiotensin II receptor blocker, telmisartan.
Francischetti EA; Celoria BM; Francischetti A; Genelhu VA
Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):289-303. PubMed ID: 18327991
[TBL] [Abstract][Full Text] [Related]
2. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
Yamagishi S; Takeuchi M
Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
[TBL] [Abstract][Full Text] [Related]
3. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension.
Benndorf RA; Rudolph T; Appel D; Schwedhelm E; Maas R; Schulze F; Silberhorn E; Böger RH
Metabolism; 2006 Sep; 55(9):1159-64. PubMed ID: 16919533
[TBL] [Abstract][Full Text] [Related]
4. Microalbuminuria and hypertension in HIV-infected patients: a preliminary study of telmisartan.
Ucciferri C; Falasca K; Mancino P; Di Iorio A; Vecchiet J
Eur Rev Med Pharmacol Sci; 2012 Apr; 16(4):491-8. PubMed ID: 22696876
[TBL] [Abstract][Full Text] [Related]
5. A meta-analysis of randomized head-to-head trials of telmisartan versus other angiotensin II receptor blocker in combination with hydrochlorothiazide for reduction of blood pressure.
Takagi H; Mizuno Y; Goto SN; Umemoto T;
Int J Cardiol; 2013 Sep; 167(6):3062-5. PubMed ID: 23200265
[No Abstract] [Full Text] [Related]
6. Rationale for double renin-angiotensin-aldosterone system blockade.
Unger T; Stoppelhaar M
Am J Cardiol; 2007 Aug; 100(3A):25J-31J. PubMed ID: 17666194
[TBL] [Abstract][Full Text] [Related]
7. Improvement of endothelial function in patients with hypertension and type 2 diabetes after treatment with telmisartan.
Wago T; Yoshimoto T; Akaza I; Tsuchiya K; Izumiyama H; Doi M; Hirata Y
Hypertens Res; 2010 Aug; 33(8):796-801. PubMed ID: 20555330
[TBL] [Abstract][Full Text] [Related]
8. Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation.
Yamagishi S; Takenaka K; Inoue H
Med Hypotheses; 2006; 66(1):118-20. PubMed ID: 16154710
[TBL] [Abstract][Full Text] [Related]
9. Telmisartan at 80 mg/day increases high-molecular-weight adiponectin levels and improves insulin resistance in diabetic patients.
Mori H; Okada Y; Arao T; Nishida K; Tanaka Y
Adv Ther; 2012 Jul; 29(7):635-44. PubMed ID: 22821644
[TBL] [Abstract][Full Text] [Related]
10. New treatment strategies for patients with hypertension and insulin resistance.
Kurtz TW
Am J Med; 2006 May; 119(5 Suppl 1):S24-30. PubMed ID: 16563944
[TBL] [Abstract][Full Text] [Related]
11. Antihypertensive and metabolic effects of telmisartan in hypertensive HIV-positive patients.
Vecchiet J; Ucciferri C; Falasca K; Mancino P; Di Iorio A; De Caterina R
Antivir Ther; 2011; 16(5):639-45. PubMed ID: 21817185
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome.
Kishi T; Hirooka Y; Konno S; Sunagawa K
J Hypertens; 2012 Aug; 30(8):1646-55. PubMed ID: 22728908
[TBL] [Abstract][Full Text] [Related]
13. Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives.
Sanchez RA; Masnatta LD; Pesiney C; Fischer P; Ramirez AJ
J Hypertens; 2008 Dec; 26(12):2393-8. PubMed ID: 19008718
[TBL] [Abstract][Full Text] [Related]
14. Telmisartan as a metabolic sartan: the first meta-analysis of randomized controlled trials in metabolic syndrome.
Takagi H; Niwa M; Mizuno Y; Goto SN; Umemoto T;
J Am Soc Hypertens; 2013; 7(3):229-35. PubMed ID: 23523138
[TBL] [Abstract][Full Text] [Related]
15. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome.
Shimabukuro M; Tanaka H; Shimabukuro T
J Hypertens; 2007 Apr; 25(4):841-8. PubMed ID: 17351377
[TBL] [Abstract][Full Text] [Related]
16. Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials.
Zou Z; Xi GL; Yuan HB; Zhu QF; Shi XY
J Hum Hypertens; 2009 May; 23(5):339-49. PubMed ID: 18987649
[TBL] [Abstract][Full Text] [Related]
17. Nifedipine and telmisartan for the treatment of hypertension: the TALENT study.
Derosa G; Maffioli P
Expert Rev Cardiovasc Ther; 2011 Dec; 9(12):1499-503. PubMed ID: 22103868
[TBL] [Abstract][Full Text] [Related]
18. The metabolic syndrome in hypertension: European society of hypertension position statement.
Redon J; Cifkova R; Laurent S; Nilsson P; Narkiewicz K; Erdine S; Mancia G;
J Hypertens; 2008 Oct; 26(10):1891-900. PubMed ID: 18806611
[TBL] [Abstract][Full Text] [Related]
19. Management issues in the metabolic syndrome.
Deedwania PC; Gupta R
J Assoc Physicians India; 2006 Oct; 54():797-810. PubMed ID: 17214277
[TBL] [Abstract][Full Text] [Related]
20. Effects of telmisartan therapy on interleukin-6 and tumor necrosis factor-alpha levels: a meta-analysis of randomized controlled trials.
Takagi H; Mizuno Y; Yamamoto H; Goto SN; Umemoto T;
Hypertens Res; 2013 Apr; 36(4):368-73. PubMed ID: 23235712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
